Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

Abstract

These data suggest that the UGT1A4 codon 48 Leu>Val polymorphism significantly alters glucuronidation rates against TAM and its active hydroxylated metabolites, and that this polymorphism may play an important role in individual pharmacological response to TAM therapy.